Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2021-004555-16
    Sponsor's Protocol Code Number:M20-429
    National Competent Authority:Italy - Italian Medicines Agency
    Clinical Trial Type:EEA CTA
    Trial Status:Trial now transitioned
    Date on which this record was first entered in the EudraCT database:2022-02-04
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedItaly - Italian Medicines Agency
    A.2EudraCT number2021-004555-16
    A.3Full title of the trial
    A Single Arm, Open-Label, Phase 1b Trial of Epcoritamab in Pediatric Patients with Relapsed/ Refractory Aggressive Mature B-cell Neoplasms
    Studio Clinico di Fase 1b, a Braccio Singolo e In Aperto di Epcoritamab in Pazienti Pediatrici con Neoplasie a Cellule B Mature Aggressive Recidivate/Refrattarie
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    This study is to evaluate the safety and pharmacokinetics of Epcoritamab in Pediatric Patients with Relapsed/ Refractory Aggressive Mature B-cell Neoplasms
    Questo studio intende valutare la sicurezza e la farmacocinetica di Epcoritamab in pazienti pediatrici affetti da neoplasie a cellule B mature aggressive recidivate/refrattarie
    A.3.2Name or abbreviated title of the trial where available
    Mature B-cell Neoplasms: Phase 1 Study of Epcoritamab in Pediatric Patients
    Neoplasie a cellule B mature: Studio clinico di Fase 1 su Epcoritamab in pazienti pediatrici
    A.4.1Sponsor's protocol code numberM20-429
    A.7Trial is part of a Paediatric Investigation Plan Yes
    A.8EMA Decision number of Paediatric Investigation PlanP/344/2021
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorABBVIE DEUTSCHLAND GMBH & CO. KG
    B.1.3.4CountryGermany
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportAbbVie Inc.
    B.4.2CountryUnited States
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationAbbVie Ltd
    B.5.2Functional name of contact pointGlobal Clinical Trials Helpdesk
    B.5.3 Address:
    B.5.3.1Street AddressAbbVie House, Vanwall Business Park, Vanwall Road
    B.5.3.2Town/ cityMaidenhead
    B.5.3.3Post codeSL6 4UB
    B.5.3.4CountryUnited Kingdom
    B.5.4Telephone number+441628561090
    B.5.5Fax number+441628461153
    B.5.6E-mailglobal-clinical-trials@abbvie.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameEpcoritamab
    D.3.2Product code [ABBV-GMAB-3013]
    D.3.4Pharmaceutical form Concentrate for solution for injection/infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPSubcutaneous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNEpcoritamab
    D.3.9.1CAS number 2134641-34-0
    D.3.9.2Current sponsor codeABBV-GMAB-3013
    D.3.9.4EV Substance CodeSUB204090
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number5
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameEpcoritamab
    D.3.2Product code [ABBV-GMAB-3013]
    D.3.4Pharmaceutical form Concentrate for solution for injection/infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPSubcutaneous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNEpcoritamab
    D.3.9.1CAS number 2134641-34-0
    D.3.9.2Current sponsor codeABBV-GMAB-3013
    D.3.9.4EV Substance CodeSUB204090
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number60
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Relapsed/refractory Burkitt's or Burkitt-like lymphoma/leukemia, Diffuse large B-cell lymphoma , or other aggressive mature (CD20+) B-cell lymphomas
    Linfoma /leucemia di Burkitt o di tipo Burkitt, linfoma diffuso a grandi cellule B oppure altri linfomi a cellule B mature aggressivi (CD20+) recidivati/refrattari
    E.1.1.1Medical condition in easily understood language
    Lymphoma of B-cell origin
    Linfoma che ha origine dalle cellule B
    E.1.1.2Therapeutic area Diseases [C] - Cancer [C04]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 21.0
    E.1.2Level PT
    E.1.2Classification code 10012822
    E.1.2Term Diffuse large B-cell lymphoma refractory
    E.1.2System Organ Class 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level HLT
    E.1.2Classification code 10006596
    E.1.2Term Burkitt's lymphomas
    E.1.2System Organ Class 100000004851
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 21.0
    E.1.2Level PT
    E.1.2Classification code 10003903
    E.1.2Term B-cell lymphoma refractory
    E.1.2System Organ Class 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    E.1.3Condition being studied is a rare disease Yes
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    The primary objectives of the study are to evaluate the safety and Pharmacokinetic profile of epcoritamab monotherapy in pediatric patients (and young adults) with relapsed/refractory Burkitt's or Burkitt-like lymphoma/leukemia, DLBCL, or other aggressive mature (CD20+) B-cell lymphomas who have failed to reach remission with re-induction therapy or who are unable to receive further consolidation with cell therapy.
    Gli obiettivi primari dello studio sono quelli di valutare il profilo di sicurezza e di farmacocinetica di epcoritamab in monoterapia in pazienti pediatrici (e in giovani adulti) affetti da linfoma/leucemia di Burkitt o di tipo Burkitt, DLBCL o altri linfomi aggressivi a cellule B mature (CD20+) recidivati/refrattari, che non sono riusciti ad ottenere la remissione con la terapia di re-induzione o non sono in grado di ricevere ulteriore trattamento di consolidamento con terapia cellulare.
    E.2.2Secondary objectives of the trial
    The secondary objective of the study is to evaluate the preliminary efficacy and immunogenicity of epcoritamab monotherapy.
    L’obiettivo secondario dello studio è quello di valutare l’efficacia preliminare e l’immunogenicità di epcoritamab in monoterapia.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. Subjects >= 1 and < 18 years old at time of primary diagnosis with Burkitt's or Burkitt-like lymphoma/leukemia, DLBCL, or other aggressive mature (CD20+) B-cell lymphomas. Patients up to 25 years of age with Burkitt's or Burkitt-like lymphoma/leukemia are also eligible.

    2. Disease pathologically confirmed (tumor tissue) by local testing.

    3. Patients with relapsed or primary refractory disease (as above) meeting any of the following criteria:
    •Progressive disease at any time during second-line chemoimmunotherapy
    •Best response of stable disease (SD) after a minimum of 2 cycles of second-line chemoimmunotherapy
    •Best response of partial response (PR) after a minimum of 3 cycles of second-line chemoimmunotherapy
    •Complete Response after a minimum of 3 cycles of second-line chemoimmunotherapy therapy but unfit or ineligible for consolidation with cell therapy
    •Not in Complete response and unable to initiate or tolerate (i.e., must discontinue) second-line chemoimmunotherapy
    •Have received cell therapy (allogeneic or autologous transplant or CAR-T therapy) as consolidation but have not obtained or maintained a complete response

    4. Recovery from toxic effects of prior chemoimmunotherapy

    5. Performance status by Lansky (< 16 years old at evaluation) or Karnofsky (>= 16 years old at evaluation) score >= 50 or ECOG score <= 2.

    6. Adequate bone marrow, hepatic, and renal function.

    7. For those patients who have not reached the age of consent, parent or legal guardian with the willingness and ability to provide written informed consent and subject willing and able to give assent, as appropriate for age and country.
    1. Soggetti di età >= 1 anno e < 18 anni al momento della diagnosi primaria di linfoma/leucemia di Burkitt o di tipo Burkitt, DLBCL, oppure altri linfomi aggressivi a cellule B mature (CD20+). Sono inoltre eleggibili pazienti di età fino a 25 anni affetti da linfoma/leucemia di Burkitt o di tipo Burkitt.

    2. Malattia con conferma istologica (tessuto tumorale) in base ad esami eseguiti localmente.

    3. Pazienti con malattia recidivata o malattia refrattaria primaria (secondo quanto indicato sopra) che soddisfino qualsiasi fra i seguenti criteri:
    • Malattia progressiva in qualsiasi momento nel corso della di chemioimmunoterapia di seconda linea
    • Miglior risposta di malattia stabile (SD) dopo un minimo di 2 cicli di chemioimmunoterapia di seconda linea
    • Miglior risposta di risposta parziale (PR) dopo un minimo di 3 cicli di chemioimmunoterapia di seconda linea
    • Risposta Completa dopo un minimo di 3 cicli di chemioimmunoterapia di seconda linea, ma condizioni generali non adeguate (unfit) oppure non idoneo al trattamento di consolidamento con terapia cellulare
    • Non in Risposta completa e non in grado di iniziare o di tollerare (in altre parole, deve interrompere) chemioimmunoterapia di seconda linea
    • Aver ricevuto terapia cellulare (trapianto allogenico o autologo oppure terapia CAR-T) come trattamento di consolidamento senza ottenere o mantenere una risposta completa

    4. Risoluzione degli effetti tossici di chemioimmunoterapia pregressa

    5. Punteggio relativo allo stato funzionale >= 50 secondo Lansky (< 16 anni al momento della valutazione) oppure Karnofsky (>= 16 anni al momento della valutazione) oppure punteggio ECOG <= 2.

    6. Funzione midollare, epatica e renale adeguate.

    7. Per i pazienti che non abbiano raggiunto la maggiore età, presenza di genitore o tutore legale disposto e in grado di fornire il consenso informato scritto, e soggetto disponibile e in grado di fornire l’assenso, secondo quanto appropriato per l’età e la nazione.
    E.4Principal exclusion criteria
    1. Known CNS involvement by lymphoma at screening as confirmed by screening MRI/CT/PET brain scans (patients with evidence of CNS disease only in the CSF will be eligible).

    2. Currently receiving anti-cancer therapy, including chemotherapy (excluding intrathecal therapy), radiotherapy, small molecules, monoclonal antibodies, cell therapy, or other investigational agents.

    3. Other malignancy requiring therapy.
    1. Noto interessamento da linfoma del sistema nervoso centrale allo screening confermato da scansioni cerebrali con RM/TAC/PET allo screening (saranno eleggibili pazienti con evidenza di malattia dell’SNC esclusivamente nel liquido cerebrospinale).

    2. Attualmente in trattamento con terapia antineoplastica, comprese chemioterapia (ad eccezione della terapia intratecale), radioterapia, farmaci a piccola molecola, anticorpi monoclonali, terapia cellulare oppure altri agenti sperimentali.

    3. Altre neoplasie maligne che necessitano di terapia.
    E.5 End points
    E.5.1Primary end point(s)
    The primary endpoints are safety and tolerability, including adverse events of special interest (AESIs) of Cytokine Release Syndrome (CRS), Immune Cell-Associated Neurotoxicity Syndrome (ICANS), and Clinical Tumor Lysis Syndrome (CTLS), and PK parameters of epcoritamab monotherapy.
    Gli endpoint primari sono la sicurezza e la tollerabilità, compresi gli eventi avversi di interesse speciale (adverse events of special interest, AESI) rappresentati da sindrome di rilascio di citochine (Cytokine Release Syndrome, CRS), sindrome da neurotossicità associata alle cellule immunitarie (Immune Cell-Associated Neurotoxicity Syndrome, ICANS) e sindrome da lisi tumorale clinica (Clinical Tumor Lysis Syndrome, CTLS), e parametri di PK per epcoritamab in monoterapia.
    E.5.1.1Timepoint(s) of evaluation of this end point
    Safety and tolerability are evaluated throughout the study.

    Pharmacokinetic parameters are evaluated the following timepoint:
    • Cycle 1: Day 10, Day 15-17, Day 19, Day 22
    • Cycle 2: Day 1, Day 8-10, Day 12, Day 15
    • Cycle 3-10: Day 1
    La sicurezza e tollerabilità verranno valutate nel corso dell’intero studio clinico

    I parametri di farmacocinetica vengono valutati alle seguenti tempistiche:
    • Ciclo 1: Giorno 10, dal Giorno 15 al Giorno 17 , Giorno 19, Giorno 22
    • Ciclo 2: Giorno 1, dal Giorno 8 al Giorno 10, Giorno 12, Giorno 15
    • Dal Ciclo 3 al Ciclo 10: Giorno 1
    E.5.2Secondary end point(s)
    •Complete response rate (CR) per the International Pediatric Non- Hodgkin Lymphoma Response Criteria
    •Event free survival (EFS)
    •Overall survival (OS)
    •Rate of initiation of stem cell transplantation or chimeric antigen receptor T-cell (CAR-T) therapy
    •Overall Response (OR)
    •Duration of response (DOR)
    •Duration of complete response (DOCR)
    •Immunogenicity (antidrug antibody [ADA] and neutralizing anti-drug antibodies [nAb])
    •Tasso di risposta completa (CR) in base ai criteri International Pediatric Non-Hodgkin Lymphoma Response Criteria
    •Sopravvivenza libera da eventi (event-free survival, EFS)
    •Sopravvivenza globale (overall survival, OS)
    •Tasso di esecuzione di trapianto di cellule staminali oppure di avvio di terapia CAR-T (chimeric antigen receptor T-cell)
    •Risposta globale (overall response, OR)
    •Durata della risposta (duration of response, DOR)
    •Durata della risposta completa (duration of complete response, DOCR)
    •Immunogenicità (anticorpi anti-farmaco [ADA] e anticorpi neutralizzanti l’effetto del farmaco [nAb])
    E.5.2.1Timepoint(s) of evaluation of this end point
    Disease evaluation (CT/MRI/PET) will be performed for all patients prior to administration of epcoritamab on Day 1 and at the following time points relative to Day 1: W6, W12, W24, W36, W48, 18 months, and 24 months, as well as prior to initiation of subsequent therapy, and as clinically indicated. Patients who do not attain a CR during therapy with epcoritamab will have additional disease assessments at W18, W30, W42, and every 3 months thereafter. Patients will be followed for a minimum of 3 years after enrollment.
    Saranno eseguite valutazioni della malattia (TAC/RM/PET) per tutti pazienti prima della somministrazione di epcoritamab il Giorno 1 e alle seguenti tempistiche rispetto al Giorno 1: Settimana 6, Settimana 12, Settimana 24, Settimana 36, Settimana 48, 18 mesi e 24 mesi, oltre che prima di avviare la terapia successiva, e secondo quanto clinicamente indicato. Per i pazienti che non ottengono una CR nel corso della terapia con epcoritamab sono previste valutazioni aggiuntive della malattia alle tempistiche Settimana 18, Settimana 30, Settimana 42 e in seguito ogni 3 mesi. I pazienti saranno seguiti per un minimo di 3 anni dopo l’arruolamento.
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response Yes
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) Yes
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other Yes
    E.7.1.3.1Other trial type description
    Phase 1b
    Fase 1b
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled No
    E.8.1.1Randomised No
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other Yes
    E.8.1.7.1Other trial design description
    a braccio singolo
    single-arm
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial1
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned2
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA18
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA Information not present in EudraCT
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Australia
    Canada
    Czechia
    France
    Germany
    Israel
    Italy
    Korea, Republic of
    Netherlands
    Russian Federation
    Spain
    Turkey
    United Kingdom
    United States
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    The end-of-study is defined as the date of the last subject's last visit or date of the last follow-up contact, whichever is later.
    Per fine dello studio si intende la data dell’ultima visita dell’ultimo soggetto oppure la data dell’ultimo contatto di follow-up, quale di questi eventi avvenga per ultimo.
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years5
    E.8.9.1In the Member State concerned months0
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years5
    E.8.9.2In all countries concerned by the trial months0
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 Yes
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) Yes
    F.1.1.4.1Number of subjects for this age range: 2
    F.1.1.5Children (2-11years) Yes
    F.1.1.5.1Number of subjects for this age range: 5
    F.1.1.6Adolescents (12-17 years) Yes
    F.1.1.6.1Number of subjects for this age range: 5
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 3
    F.1.3Elderly (>=65 years) No
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally Yes
    F.3.3.6.1Details of subjects incapable of giving consent
    Pediatric patients
    Pazienti pediatrici
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state6
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 7
    F.4.2.2In the whole clinical trial 15
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Upon completion of the study, the subjects will be treated in accordance with the Investigator's best clinical judgement
    Una volta completato lo studio, i soggetti saranno trattati secondo il miglior giudizio clinico del medico sperimentatore.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2022-07-21
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2022-03-22
    P. End of Trial
    P.End of Trial StatusTrial now transitioned
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 03 07:21:53 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA